Tang WHo, Stitham J, Jin Y, Liu R, Lee SHee, Du J, Atteya G, Gleim S, Spollett G, Martin K et al..  2014.  Aldose reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets. Circulation. 129(15):1598-609.
Jiang Y, Djuric Z, Sen A, Ren J, Kuklev D, Waters I, Zhao L, Uhlson CL, Hong YH, Murphy RC et al..  2014.  Biomarkers for personalizing omega-3 fatty acid dosing. Cancer Prev Res (Phila). 7(10):1011-22.
Vanichakarn P, Hwa J, Stitham J.  2014.  Cardiovascular pharmacogenetics of antihypertensive and lipid- lowering therapies. Curr Mol Med. 14(7):849-79.
Stitham J, Vanichakarn P, Ying L, Hwa J.  2014.  Cardiovascular pharmacogenetics of anti-thrombotic agents and non-steroidal anti-inflammatory drugs. Curr Mol Med. 14(7):909-31.
Sahu RP, Ocana JA, Harrison KA, Ferracini M, Touloukian CE, Al-Hassani M, Sun L, Loesch M, Murphy RC, Althouse SK et al..  2014.  Chemotherapeutic agents subvert tumor immunity by generating agonists of platelet-activating factor. Cancer Res. 74(23):7069-78.
Toung JM, Lahens N, Hogenesch JB, Grant G.  2014.  Detection theory in identification of RNA-DNA sequence differences using RNA-sequencing. PLoS One. 9(11):e112040.
Li X, Fries S, Li R, Lawson JA, Propert KJ, Diamond SL, Blair IA, FitzGerald GA, Grosser T.  2014.  Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 111(47):16830-5.
Moore JH, Hwa J.  2014.  Editorial: pharmacogenetics and molecular medicine: "so close and yet so far". Curr Mol Med. 14(7):803-4.
Lu Y-C, Chang S-H, Hafner M, Li X, Tuschl T, Elemento O, Hla T.  2014.  ELAVL1 Modulates Transcriptome-wide miRNA Binding in Murine Macrophages. Cell Rep. 9(6):2330-43.
Chang S-H, Elemento O, Zhang J, Zhuang ZW, Simons M, Hla T.  2014.  ELAVL1 regulates alternative splicing of eIF4E transporter to promote postnatal angiogenesis. Proc Natl Acad Sci U S A. 111(51):18309-14.
Keramati AR, Fathzadeh M, Go G-W, Singh R, Choi M, Faramarzi S, Mane S, Kasaei M, Sarajzadeh-Fard K, Hwa J et al..  2014.  A form of the metabolic syndrome associated with mutations in DYRK1B. N Engl J Med. 370(20):1909-19.
Obinata H, Gutkind S, Stitham J, Okuno T, Yokomizo T, Hwa J, Hla T.  2014.  Individual variation of human S1P1 coding sequence leads to heterogeneity in receptor function and drug interactions. J Lipid Res. 55(12):2665-75.
Gottlieb A, Altman RB.  2014.  Integrating systems biology sources illuminates drug action. Clin Pharmacol Ther. 95(6):663-9.
Chakraborty R, Bhullar RP, Dakshinamurti S, Hwa J, Chelikani P.  2014.  Inverse agonism of SQ 29,548 and Ramatroban on Thromboxane A2 receptor. PLoS One. 9(1):e85937.
Zarini S, Hankin JA, Murphy RC, Gijón MA.  2014.  Lysophospholipid acyltransferases and eicosanoid biosynthesis in zebrafish myeloid cells. Prostaglandins Other Lipid Mediat. 113-115:52-61.
Martin SA, Gijón MA, Voelker DR, Murphy RC.  2014.  Measurement of lysophospholipid acyltransferase activities using substrate competition. J Lipid Res. 55(4):782-91.
Chen EP, Markosyan N, Connolly E, Lawson JA, Li X, Grant GR, Grosser T, FitzGerald GA, Smyth EM.  2014.  Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function. Carcinogenesis. 35(8):1788-97.
O'Donnell VB, Murphy RC, Watson SP.  2014.  Platelet lipidomics: modern day perspective on lipid discovery and characterization in platelets. Circ Res. 114(7):1185-203.
Snyder NW, Basu SS, Zhou Z, Worth AJ, Blair IA.  2014.  Stable isotope dilution liquid chromatography/mass spectrometry analysis of cellular and tissue medium- and long-chain acyl-coenzyme A thioesters. Rapid Commun Mass Spectrom. 28(16):1840-8.
Roberts LD, Koulman A, Griffin JL.  2014.  Towards metabolic biomarkers of insulin resistance and type 2 diabetes: progress from the metabolome. Lancet Diabetes Endocrinol. 2(1):65-75.